Results 101 to 110 of about 4,333 (186)

Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons

Journal of Pain Research, 2011
Yiangos Yiangou1 Uma Anand1,2, William R. Otto2, Marco Sinisi3, Michael Fox3, Rolfe Birch3 Keith A. Foster4, Gaurav Mukerji1,5, Ayesha Akbar1,6, Sanjiv K.
Yiangou Y, An, U, Otto WR, Sinisi M, Fox M, Birch R, Foster KA, Mukerji G, Akbar A, Agarwal SK, An, P   +12 more
doaj  

Type E Botulinum Neurotoxin-Producing Clostridium butyricum Strains Are Aerotolerant during Vegetative Growth

mSystems, 2019
Clostridium butyricum, the type species of the genus Clostridium, is considered an obligate anaerobe, yet it has been shown to grow in the presence of oxygen. C. butyricum strains atypically producing the botulinum neurotoxin type E are the leading cause
Serena Camerini, Lucia Marcocci, Lara Picarazzi, Egidio Iorio, Irene Ruspantini, Paola Pietrangeli, Marco Crescenzi, Giovanna Franciosa   +7 more
doaj   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

Developmental Medicine &Child Neurology, Volume 68, Issue 6, Page 792-799, June 2026.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H. Goldsmith, Unni Narayanan, Peter L. Rosenbaum, F. Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group, Timothy Carey, Mark Mason, Ronit Mesterman   +11 more
wiley   +1 more source

Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports

, 2013
Sebastian Torres,1 Mark Hamilton,2 Elena Sanches,4 Polina Starovatova,3 Elena Gubanova,3 Tatiana Reshetnikova51Di Stefano Velona Clinic, Catania, Italy; 2Hamilton Face Clinic, Dublin, Ireland; 3Preventive Medicine Clinic "Vallex M", Moscow ...
Sanches E, Starovatova P, Reshetnikova T, Gubanova E, Torres S, Hamilton M   +5 more
core  

Structure of dual receptor binding to botulinum neurotoxin B

, 2013
Botulinum neurotoxins are highly toxic, and bind two receptors to achieve their high affinity and specificity for neurons. Here we present the first structure of a botulinum neurotoxin bound to both its receptors.
Dong, M., Stenmark, P., Peng, Lisheng, Dong, Min, Stenmark, Pål,, Berntsson, R.P. A., Berntsson, Ronnie P. A.,, Peng, L.   +7 more
core   +1 more source

An Investigation of Immunogenicity of Chitosan-Based Botulinum Neurotoxin E Binding Domain Recombinant Candidate Vaccine via Mucosal Route

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2017
Background and Objectives: Botulism syndrome is caused by serotypes A-G of neurotoxins of Clostridium genus. Neurotoxin binding domain is an appropriate vaccine candidate due to its immunogenic activity.
Mohammad Javad Bagheripour, Firouz Ebrahim, Abbas Hajizadeh, Shahram Nazarian, Jamil Zargan, Jamal Rashidiani   +5 more
doaj  

Electrochemical impedance spectroscopy biosensor for detection of active botulinum neurotoxin

Sensing and Bio-Sensing Research, 2014
The standard method for the detection of botulinum neurotoxin is currently the mouse bioassay which is considered to be the most reliable method for the detection of the active form of this toxin.
Jennifer Halliwell, Alison C. Savage, Nicholas Buckley, Christopher Gwenin   +3 more
doaj   +1 more source

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Despite the increasing use of botulinum toxin type A (BoNT‐A) in aesthetic and therapeutic applications, its real‐world adverse drug reaction (ADR) profile remains incompletely characterized. Current evidence relies largely on small‐scale clinical observations rather than large, systematic analyses.
Jiaxu Gu, Yue Sun, Kexin Chen, Jieyi Wang, Bingcheng Lu, Hongqiang Xie, Xiaoming Liu, Cong Huang, Xingling Jian, Bo Yu   +9 more
wiley   +1 more source

Phenol Neurolysis in Pain and Palliative Medicine

Pain Practice, Volume 26, Issue 5, June 2026.
ABSTRACT Background Pain is a common symptom in palliative care and affects patients' quality of life considerably. Standard analgesics are sometimes insufficient and are associated with substantial side effects. Neurolysis, the targeted destruction of nerves using thermal or chemical agents, offers an additional option for managing localized pain in ...
Jeroen H. A. Creemers, Rachel J. H. Smits, Alopi M. Patel, Robert T. M. van Dongen, Cornelis K. Kramers, Jacqueline M. Bos, Selina E. I. van der Wal   +6 more
wiley   +1 more source

Exploring the functional domain and the target of the tetanus toxin light chain in neurohypophysial terminals [PDF]

, 1994
The tetanus toxin light chain blocks calcium induced vasopressin release from neurohypophysial nerve terminals. Here we show that histidine residue 233 within the putative zinc binding motif of the tetanus toxin light chain is essential for the ...
Weller, U., Dayanithi, G., Yamasaki, S., Niemann, H., Gratzl, Manfred, Stecher, B., Höhne-Zell, B., Binz, T.   +7 more
core   +1 more source